Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Vor Biopharma Inc

VOR ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$23.03

▼ -1.12%

Market Cap $1.36B · Vol 131.54K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.36B

Small Cap

Div Yield

N/A

EPS Growth

+90.58%

YoY

RSI (14)

68.95

Momentum

Beta

1.71

vs Market

52W High

$50.10

54.03% below

52W Low

$6.51

253.76% above

Volume

131.54K

Avg 316.74K

P/B

N/A

Price-to-book

ROE

2,057.66%

Return on equity

Free Float

91.87%

Public shares

Shariah Compliance8 STANDARDS

✗ Vor Biopharma Inc (VOR) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does VOR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.70%

+24.49%

+52.82%

+80.20%

YTD

+76.07%

-41.84%

-60.43%

-91.86%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-695,981,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	2,057.66%
ROA · ROIC	-229.31% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+90.58%
Outstanding Shares	59.16M

Technical Indicators

50-Day SMA	$18.40
200-Day SMA	$15.24
RSI (14)	68.95
Beta	1.71
52-Week High	$50.10
52-Week Low	$6.51

Volume Today	131.54K
Avg Daily Volume (30D)	316.74K
Relative Volume	0.42x
Volatility (10D)	49.64
Volatility (30D)	69.17
Free Float	91.87%

Analyst Consensus

BUY

Current Price $23.03

Mean Target $39.00

52W Low$6.51 52W High$50.10

Current

Target

$6.51 $50.10

Current Analyst target

+69.34% upside potential · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00NBJRDV3

ISINUS9290332074

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.